[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,762,434
  • Shares Outstanding, K 134,949
  • Annual Sales, $ 0 K
  • Annual Income, $ -287,860 K
  • EBIT $ -172 M
  • EBITDA $ -172 M
  • 60-Month Beta 2.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.70

Options Overview Details

View History
  • Implied Volatility 95.91% (+2.13%)
  • Historical Volatility 126.43%
  • IV Percentile 32%
  • IV Rank 11.47%
  • IV High 287.30% on 06/20/25
  • IV Low 71.12% on 05/14/26
  • Expected Move (DTE 19) 1.79 (13.67%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 14,900
  • Volume Avg (30-Day) 7,157
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 100,320
  • Open Int (30-Day) 109,264
  • Expected Range 11.28 to 14.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.51
  • Number of Estimates 7
  • High Estimate $-0.31
  • Low Estimate $-0.72
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -34.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.22 +58.88%
on 04/30/26
13.10 -0.31%
on 05/29/26
+4.68 (+55.85%)
since 04/29/26
3-Month
4.88 +167.62%
on 03/24/26
13.10 -0.31%
on 05/29/26
+6.16 (+89.28%)
since 02/27/26
52-Week
2.25 +480.44%
on 06/23/25
13.10 -0.31%
on 05/29/26
+8.84 (+209.48%)
since 05/28/25

Most Recent Stories

More News
Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to...

CMPS : 13.06 (+9.56%)
SPRO : 2.83 (-2.41%)
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies...

CMPS : 13.06 (+9.56%)
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant...

CMPS : 13.06 (+9.56%)
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC...

CMPS : 13.06 (+9.56%)
Compass Pathways Q1 Earnings Call Highlights

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for...

CMPS : 13.06 (+9.56%)
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating...

CMPS : 13.06 (+9.56%)
Can Compass Pathways Justify Its Valuation Before the FDA Clock Actually Starts?

Barchart Research What to Expect from CMPS Earnings CMPS Generated May 12, 2026 Current Price $9.37 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 8.00% Can Compass Pathways Justify Its...

CMPS : 13.06 (+9.56%)
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

Compass management will host a conference call at 8:00 am ET (1:00 pm UK) 

CMPS : 13.06 (+9.56%)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...

CMPS : 13.06 (+9.56%)
Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?

CMPS : 13.06 (+9.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 14.81
2nd Resistance Point 13.95
1st Resistance Point 13.51
Last Price 13.06
1st Support Level 12.21
2nd Support Level 11.35
3rd Support Level 10.91

See More

52-Week High 13.10
Last Price 13.06
Fibonacci 61.8% 8.96
Fibonacci 50% 7.68
Fibonacci 38.2% 6.39
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.